Biophytis Sa · EURONEXT:ALBPS
Biophytis Sa — Investor Presentation (August 2026)
19 slides from Biophytis Sa's investor presentation, August 2026
Slide 1: A pioneering biotechnology company focused on therapies that impact longevity
August 2026 A pioneering biotechnology company focused on developing transformative therapies that impact longevity Founded on pioneering science from researchers at
Slide 2: A pioneering biotechnology company focused on developing transformative therapies that impact longevity
A pioneering biotechnology company focused on developing transformative therapies that impact longevity Founded on pioneering science from researchers at
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as «outlook », «believes», «expects», «potentia
Slide 4: Mission & Vision
bfophytis Mission & Vision Advancing Longevity by discovering new targets and drug candidates addressi fundamental needs in human aging
Slide 5: Our leadership team has a proven track record across drug discovery, development, and commercialization
Our leadership team has a proven track record across drug discovery, development, and commercialization Management Committee Cumulative years of experience Broad Experience in BioPharma and beyond S tan isla s Ve illet C hief E xec utive O fficer E do ua rd Bieth C hief S trateg y O fficer 176y 126y
Slide 6: Our 3 Strategic R&D programs
Our 3 Strategic R&D programs Longevity AI-powered Discovery BIO101 in Sarcopenia BIO101 in Obesity A unique platform combining The world’s most advanced A unique program targeting several technologies accelerated by clinical program in sarcopenia mobility in patients suffering AI for the discovery o
Slide 7: Our research explores and identifies the fundamental mechanisms of aging
Our research explores and identifies the Longevity AI-powered Discovery fundamental mechanisms of aging to develop new therapeutic solutions… Alzheimer’s Frailty and Disease and Cardiovascular Muscular Dementia Diseases diseases Diabetes Chronic Osteoarthritis and Obstructive Osteoporosis Pulmonary
Slide 8: AI-accelerated platform for the discovery of drug candidates impacting longevity
AI-accelerated platform for the discovery Longevity AI-powered Discovery of drug candidates impacting longevity AI-enabled target ID & validation Technology Assessment & Lead ID AI Screening & Candidate selection Exploration Expertise across discovery and development with a We use 2 types of screeni
Slide 9: BIO101: Our drug candidate is an oral small molecule
BIO101 : Our drug candidate is an oral small molecule potential for best in class acting on the root cause of muscle wasting First in class molecule Ease of administration • Validated mechanism of action • API manufactured at industrial scale • Activation of MAS receptor (protective • Advanced CMC a
Slide 10: Sarcopenia, an exploding market with no therapeutic solution as of today
Sarcopenia, an exploding market with no BIO101 in Sarcopenia therapeutic solution as of today No pharmacological treatment Sarcopenia is a disorder defined has yet been approved, only consensually by several limited options exist consortia (FNIH, EWGSOP, SDOC and ESCEO), characterized by up to 1/4 p
Slide 11: BIO101 is the most advanced drug candidate in sarcopenia
BIO101 is the most advanced drug candidate BIO101 BIO101in in Sarcopenia Sarcopenia in sarcopenia Administration Drug Company Technology Main Endpoints Safety & Side effects Status route High Dose showed Excellent tolerability Phase 3 BIO101 MAS Receptor promising results on profile and no serious o
Slide 12: In Phase 2, BIO101 improved mobility of patients suffering from sarcopenia
In Phase 2, BIO101 improved mobility BIO101 BIO101in in Sarcopenia Sarcopenia of patients suffering from sarcopenia BIO101 350mg BID versus placebo : Gait Speed Improvement Fielding 2025 et al. Journal of Cachexia, Sarcopenia and Muscle, 2025; 16:e13750 +11%
Slide 13: First Phase 3 in sarcopenia: partnership formation in Asia
We aim at conducting the first Phase 3 ever in sarcopenia to confirm the clinical efficacy of BIO101 BIO101 BIO101in in Sarcopenia Sarcopenia in a larger population Targeted Indication Treatment of severe sarcopenia in older patients (≥65 years) who are at risk of mobility disability Partneship Form
Slide 14: The vast majority of patients suffering from obesity have mobility issues
The vast majority of patients suffering from BIO101 in Obesity Obesity have mobility issues 96% of obese patients have impaired muscle strength(2) (1) https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth (2) Vale nzuela et al. BMC Musculoskeletal Disorders
Slide 15: A unique program targeting mobility in patients suffering from obesity
A unique program targeting mobility in BIO101 in Obesity patients suffering from obesity Strong Proof of concept (1) A Phase 2 targeting muscle quality in obesity Partnership established Sample size : 164 patients License agreement in LATAM signed with BLANVER Target population: PHARMA Obese patient
Slide 16: Major upcoming milestones on our R&D programs
Major upcoming milestones on our 3 R&D programs Longevity AI-powered Discovery BIO101 in Sarcopenia BIO101 in Obesity ACHIEVED ACHIEVED ACHIEVED ✓ Agreement signed between BIOPHYTIS and its ✓ BIO101 + GLP-1 animal studies results ✓ Partnership signed with LynxKite in AI partners, including RONGHUI R
Slide 17: Our Pipeline: Transformative therapies that impact longevity
Our Pipeline: Transformative therapies that impact longevity IND Candidate Indication Program Discovery Lead Op Enabling Phase 1 Phase 2 Phase 3 Registration Strategic Programs BIO101 Sarcopenia SARA BIO101 Obesity OBA AI- Age-related metabolic and Powered neurodegenerative Discovery diseases Stand-
Slide 18: Financial data
Financial data Shareholding structure Key financials Listing Euronext (ALBPS) and US market (OTC) Institutional Investors US* Floating ▪ Cash position: €190k (December 31, 2025) and Others 15% ▪ Hexagon bond facility: € 2m Institutional 13% Investors EU 72% Analyst Coverage Jamila El Bougrini Notewo
Slide 19: Mission & Vision
Longevity AI-powered Discovery A unique platform combining several technologies accelerated by AI for the discovery of new drug candidates impacting longevity Mission & Vision BIO101 in Sarcopenia The world’s most advanced clinical program in sarcopenia BIO101 in Obesity A unique program targeting m